-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the new coronavirus variant named Omicron (B.
Since the beginning of 2021, Moderna has been pursuing a comprehensive R&D strategy for possible new variants.
First, Moderna has tested the effect of a higher dose booster vaccine (100 μg) in healthy volunteers
Secondly, Moderna has tested two multivalent enhanced vaccine candidates in clinical trials.
Finally, Moderna is rapidly advancing the development of a candidate booster vaccine (mRNA-1273.
Reference materials:
[1] Moderna Announces Strategy to Address Omicron (B.